InxMed Limited

Late-stage biotechnology company developing small-molecule oncology drugs, focusing on a FAK inhibitor, ifebemtinib, in registrational studies in China for tumor treatment resistance.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Losses and path to profitability
• Cash burn and runway
• Preferred shares and fair-value liabilities
• Adverse change after the track record
• Non-IFRS measures and adjustments
• Chapter 18A biotech